Skip to content
Evigrade
CriticalSelective serotonin 5HT1B/1D agonists (triptans)×Antidepressants. Other antidepressants of herbal origin

Updated · Methodology

Mechanism

St John's wort extract inhibits the synaptosomal reuptake of serotonin, noradrenaline and dopamine (St John's wort summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Almotriptan is a selective serotonin 5-HT1 receptor agonist (almotriptan SmPC, AEMPS, section 5.1). The interaction table of the St John's wort SmPC lists increased serotonergic effects and a higher incidence of adverse reactions with triptans, including almotriptan (St John's wort SmPC, AEMPS, section 4.5). The almotriptan SmPC also states that adverse reactions may be more common when triptans are used with St John's wort preparations (almotriptan SmPC, AEMPS, section 4.4). St John's wort induces CYP3A4 (St John's wort SmPC, AEMPS, sections 4.5 and 5.2). CYP3A4 takes part in almotriptan metabolism together with the main enzyme, monoamine oxidase A (almotriptan SmPC, AEMPS, section 5.2). The documents do not describe how St John's wort changes almotriptan levels.

Symptoms

The St John's wort summary of product characteristics (SmPC) warns of increased serotonergic effects and more frequent adverse reactions when St John's wort is combined with triptans (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). According to the European Medicines Agency (EMA) herbal monograph, serotonin syndrome can occur very rarely in combination with serotonin reuptake inhibitors or other serotonergic substances (St John's wort herbal monograph, EMA, section 4.5). Potentially life-threatening serotonin syndrome may occur with triptans, including almotriptan, particularly with selective serotonin reuptake inhibitors (SSRIs) or serotonin-noradrenaline reuptake inhibitors (SNRIs) (almotriptan label, US Food and Drug Administration, FDA, section 5.5). The label does not mention St John's wort. According to this label, signs include agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, nausea, vomiting and diarrhoea (FDA almotriptan label, section 5.5).

Management

The Spanish St John's wort summary of product characteristics (SmPC) contraindicates the combination: St John's wort must not be used with medicines of the triptan group, and its interaction table names almotriptan (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). The authorisation of this product has been suspended since 11 June 2026, and there is no other current Spanish St John's wort SmPC. The almotriptan documents are less strict. The Spanish almotriptan SmPC states that adverse reactions may be more common with St John's wort preparations but does not prohibit the combination (almotriptan SmPC, AEMPS, section 4.4). The almotriptan label of the US Food and Drug Administration (FDA) does not mention St John's wort. The almotriptan documents do not say whether to stop almotriptan if serotonin syndrome is suspected. Nor do they say how long to wait between stopping St John's wort and taking almotriptan.

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Almotriptan

Other interactions with Hypericum perforatum